Abicipar, the first and only anti-VEGF to maintain stable vision in greater than 91 percent of patients on a fixed 12-week regimen, achieved the primary endpoint of non-inferiority to monthly ranibizumab at week 52 Two pivotal head-to-head trials demonstrate the efficacy of Abicipar 12-week fixed

Zurich-Schlieren, June 21, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today the appointment of Pamela A. Trail, Ph.D., as Chief Scientific Officer.

MP0250 is evaluated in combination with Velcade/Dexamethasone (VelDex) in relapsed/refractory multiple myeloma (MM) patients Five of eight patients (62.5%) with relapsed/refractory multiple myeloma showed an objective response to MP0250 plus VelDex Median duration on treatment for patients with

Zurich-Schlieren, May 16, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that the complete safety and efficacy results of the Phase 1 study of its lead proprietary oncology drug,

Zurich-Schlieren, Apil 21, 2018.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that preliminary results from the ongoing Phase 2 study of MP0250 with bortezomib and dexamethasone in

Zurich-Schlieren, Apil 18, 2018. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected William (Bill) Burns as new Chairman of the Board.

Research & Development: MP0250 in multiple myeloma (MM): Promising initial safety and efficacy data from the ongoing phase 2 study of MP0250 reconfirmed with updated data presented at the European Myeloma Network Meeting  in Turin on April 21 MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR

Zurich-Schlieren, Apil 11, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that Molecular Partners and AstraZeneca (LON: AZN) will collaborate on Molecular Partners’ ongoing phase

Zurich-Schlieren, Apil 05, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that new pre-clinical data from two of its pipeline candidates, MP0310 and its lead proprietary oncology

Zurich-Schlieren, March 21, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today published the invitation to the Annual General Meeting 2018. The Annual General Meeting will be held on Wednesday,